当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.

Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.

Abstract：

:The aromatase inhibitor 10-propargylestr-4-ene-3,17-dione (PED) has been evaluated in vivo as an anticancer agent. Prolonged administration of PED to rats bearing dimethylbenzanthracene-induced mammary tumors resulted in significant regression of hormone-responsive tumors within several days. Greater than 50% regression was generally observed after 14 days of treatment, irrespective of dose (1, 5, or 50 mg/kg body weight/day). In addition to tumor regression, a significantly increased incidence in tumor stasis was observed over the course of PED treatment. While all doses of PED examined were equipotent for both tumor regression and stasis, a dose-dependent inhibition of new tumor formation was observed in PED-treated rats. In control animals an average of 1.2 new tumors was observed during the experimental period; in contrast, averages of 0.5 tumors appeared in animals receiving 1 mg PED/kg body weight/day, 0.1 tumors at 5 mg/kg, and at 50 mg of PED/kg body weight/day, no new tumors occurred during the time PED was administered. The effects of PED on both regression of existing tumors and appearance of new tumors were reversed by co-administration of estradiol. Thus, PED impairs estrogen-dependent mammary tumor growth, resulting in cessation of new growth and regression of responsive tumors.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Zimniski SJ,Brandt ME,Covey DF,Puett D

doi

10.1007/BF00682696

subject

Has Abstract

pub_date

1993-01-01 00:00:00

pages

15-21

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

26

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

    abstract：:Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6-15 years after cancer diagnosis to matched women free of breast cancer at start ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3021-8

    authors： Jordan JH,Thwin SS,Lash TL,Buist DS,Field TS,Haque R,Pawloski PA,Petersen HV,Prout MN,Quinn VP,Yood MU,Silliman RA,Geiger AM

    更新日期：2014-07-01 00:00:00

  • The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

    abstract：:The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it wi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3308-4

    authors： Jerjees DA,Negm OH,Alabdullah ML,Mirza S,Alkaabi M,Hameed MR,Abduljabbar R,Muftah A,Nolan CC,Green AR,Tighe PJ,Band V,Ellis IO,Rakha EA

    更新日期：2015-02-01 00:00:00

  • Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.

    abstract：:Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period cha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0615-7

    authors： Lambe M,Wigertz A,Holmqvist M,Adolfsson J,Bardage C,Fornander T,Karlsson P,Odlind V,Persson I,Ahlgren J,Bergkvist L

    更新日期：2010-06-01 00:00:00

  • Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.

    abstract：PURPOSE:In order to better define the breast cancer (BC) genetic risk factors in men, a germline investigation was carried out on 81 Male BC cases by screening the 24 genes involved in BC predisposition, genome stability maintenance and DNA repair mechanisms by next-generation sequencing. METHODS:Germline DNAs were te...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05429-z

    authors： Scarpitta R,Zanna I,Aretini P,Gambino G,Scatena C,Mei B,Ghilli M,Rossetti E,Roncella M,Congregati C,Bonci F,Naccarato AG,Palli D,Caligo MA

    更新日期：2019-12-01 00:00:00

  • Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands.

    abstract：:To compare overall survival between women with unilateral breast cancer (UBC) and contralateral breast cancer (CBC). Women with UBC (N = 182,562; 95 %) and CBC (N = 8,912; 5 %) recorded in the Netherlands Cancer Registry between 1989 and 2008 were included and followed until 2010. We incorporated CBC as a time-depende...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2588-9

    authors： Font-Gonzalez A,Liu L,Voogd AC,Schmidt MK,Roukema JA,Coebergh JW,de Vries E,Soerjomataram I

    更新日期：2013-06-01 00:00:00

  • GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.

    abstract：:Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk. Regarding GSTT1 and GSTP1 polymorphisms, studies remain controversial and no recent...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-009-0520-0

    authors： Sergentanis TN,Economopoulos KP

    更新日期：2010-05-01 00:00:00

  • Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy.

    abstract：PURPOSE:The selective treatment of internal mammary lymph nodes (IMNs) in breast cancer is controversial. The purpose of this research was to determine the subpopulation patients with high risk of internal mammary lymph nodes metastasis who received extended radical mastectomy without any preoperative treatment from 19...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9561-4

    authors： Huang O,Wang L,Shen K,Lin H,Hu Z,Liu G,Wu J,Lu J,Shao Z,Han Q,Shen Z

    更新日期：2008-02-01 00:00:00

  • High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.

    abstract：PURPOSE:Cyclin D1 has a central role in cell cycle control and is an important component of estrogen regulation of cell cycle progression. We have previously shown that high cyclin D expression is related to aggressive features of ER-positive but not ER-negative breast cancer. The aims of the present study were to vali...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4294-5

    authors： Ahlin C,Lundgren C,Embretsén-Varro E,Jirström K,Blomqvist C,Fjällskog M-

    更新日期：2017-08-01 00:00:00

  • Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.

    abstract：:MicroRNAs play a role in breast cancer development and progression by post-transcriptional repression of the expression of important genes, such as the tumor suppressor gene phosphatase and tensin homolog (PTEN). The focus of the current study was to examine the diagnostic potential of circulating cell-free microRNAs ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-1988-6

    authors： Schwarzenbach H,Milde-Langosch K,Steinbach B,Müller V,Pantel K

    更新日期：2012-08-01 00:00:00

  • Adjuvant systemic therapy: state of the art, 1989.

    abstract：:After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验,评审

    doi：10.1007/BF01805971

    authors： Henderson IC

    更新日期：1989-10-01 00:00:00

  • Four cases of chylous fistula after breast cancer resection.

    abstract：:Chylous fistulas in cases treated surgically for breast cancer only, are rare. We encountered four chylous fistula cases after breast cancer operations out of a total of 851 cases, all of which involved the left breast. Chylous fistulas were confirmed by axillary white fluid and were unrelated to obesity, surgical met...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000010675.87358.b6

    authors： Nakajima E,Iwata H,Iwase T,Murai H,Mizutani M,Miura S,Kato H

    更新日期：2004-01-01 00:00:00

  • Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status.

    abstract：:Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004-2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0354-9

    authors： Zhang M,Yang H,Holman CD

    更新日期：2009-12-01 00:00:00

  • Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

    abstract：:Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-013-2611-1

    authors： Russo AL,Taghian AG

    更新日期：2013-07-01 00:00:00

  • Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.

    abstract：:Chromosomal instability is a known hallmark of many cancers. DNA polymerases represent a group of enzymes that are involved in the mechanism of chromosomal instability as they have a central function in DNA metabolism. We hypothesized that genetic variation in the polymerase genes may affect gene expression or protein...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1460-z

    authors： Varadi V,Bevier M,Grzybowska E,Johansson R,Enquist K,Henriksson R,Butkiewicz D,Pamula-Pilat J,Tecza K,Hemminki K,Lenner P,Försti A

    更新日期：2011-08-01 00:00:00

  • Effect of chemotherapy on survival in metastatic breast cancer.

    abstract：:In order to assess the impact of modern combination chemotherapy on overall survival of metastatic breast cancer patients, we retrospectively analysed survival data of those patients who presented with breast cancer and developed metastases at our clinic from 1971-78 inclusive. Our results indicate a trend towards imp...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806751

    authors： Paterson AH,Szafran O,Cornish F,Lees AW,Hanson J

    更新日期：1981-01-01 00:00:00

  • Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.

    abstract：:Mutations in the BRCA1 and BRCA2 genes account for the majority of hereditary breast ovarian cancer (HBOC) cases. However, after BRCA1 and BRCA2 screening still the most HBOC cases remain negative for any mutational event. Accordingly, in these cases raises the relevance to analyze the unusual BRCA1/2 variants of unce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0244-6

    authors： Konecny M,Vizvaryova M,Zavodna K,Behulova R,Gerykova Bujalkova M,Krivulcik T,Cisarik F,Kausitz J,Weismanova E

    更新日期：2010-01-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract：PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05543-3

    authors： Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期：2020-04-01 00:00:00

  • Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

    abstract：PURPOSE:The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors. METHODS:Of the 53,670 patients registered between 2004 and 2006 and su...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3984-8

    authors： Kataoka A,Iwamoto T,Tokunaga E,Tomotaki A,Kumamaru H,Miyata H,Niikura N,Kawai M,Anan K,Hayashi N,Masuda S,Tsugawa K,Aogi K,Ishida T,Masuoka H,Iijima K,Kinoshita T,Nakamura S,Tokuda Y

    更新日期：2016-11-01 00:00:00

  • A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (

    abstract：PURPOSE:Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer trastuzumab resistance. A combination of SAHA and trastuzumab may be a promising strategy to improve the efficacy of trastuzumab against breast cancer. In this Pha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4310-9

    authors： Goldstein LJ,Zhao F,Wang M,Swaby RF,Sparano JA,Meropol NJ,Bhalla KN,Pellegrino CM,Katherine Alpaugh R,Falkson CI,Klein P,Sledge GW

    更新日期：2017-09-01 00:00:00

  • Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.

    abstract：:Aromatase inhibitors (AIs) are used for treatment of estrogen receptor α (ER)-positive breast cancer; however, resistance is a major obstacle for optimal outcome. This preclinical study aimed at identifying potential new treatment targets in AI-resistant breast cancer cells. Parental MCF-7 breast cancer cells and four...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3284-8

    authors： Hole S,Pedersen AM,Lykkesfeldt AE,Yde CW

    更新日期：2015-02-01 00:00:00

  • Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome.

    abstract：BACKGROUND:We report a novel BRCA1 LGR, involving the complete duplication of exon 3, in an Italian patient with a strong family history of breast and ovarian cancer. Our purpose is to provide an effective characterization of this LGR using a combination of different methods able to establish the exact breakpoints of t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4275-8

    authors： Concolino P,Rizza R,Hackmann K,Paris I,Minucci A,De Paolis E,Scambia G,Zuppi C,Schrock E,Capoluongo E

    更新日期：2017-07-01 00:00:00

  • Is there a role for sentinel node biopsy in the pre-operative ultrasound positive axilla?

    abstract：:Axillary management in breast cancer is becoming increasingly conservative. This approach is based on the identification of low axillary burden on sentinel node biopsy (SNB). The modern practice of routine pre-operative axillary ultrasound has meant that patients are 'fast tracked' to axillary node clearance (ANC) in ...

    journal_title：Breast cancer research and treatment

    pub_type： 社论

    doi：10.1007/s10549-017-4313-6

    authors： Ahmed M,Jozsa F,Douek M

    更新日期：2017-09-01 00:00:00

  • Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.

    abstract：:The positive effects of tamoxifen (TAM) on breast cancer recurrence and survival as well as on overall mortality have led to its use as the predominant adjuvant therapy among women with breast cancer. However, the association of TAM intake with undesirable side effects has been reported in numerous studies. This analy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000021050.92539.b0

    authors： Gallicchio L,Lord G,Tkaczuk K,Danton M,Lewis LM,Lim CK,Flaws JA

    更新日期：2004-05-01 00:00:00

  • Sexual health in long-term breast cancer survivors.

    abstract：PURPOSE:Sexual dysfunction is reported in women with breast cancer (BC). It is unclear whether symptoms persist over time as data comparing long-term survivors to controls are lacking. We compared sexual functioning in long-term breast cancer survivors (BCS) to controls and determined the impact of adjuvant therapy on ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4894-8

    authors： Soldera SV,Ennis M,Lohmann AE,Goodwin PJ

    更新日期：2018-11-01 00:00:00

  • MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

    abstract：:The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary lymphatic spread in breast cancer patients. Biopsies from breast cancer (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9400-z

    authors： Bathen TF,Jensen LR,Sitter B,Fjösne HE,Halgunset J,Axelson DE,Gribbestad IS,Lundgren S

    更新日期：2007-08-01 00:00:00

  • Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.

    abstract：:While overall survival (OS) has historically been the primary endpoint for clinical trials in oncology, progression-free survival (PFS) has gained acceptance as a valuable surrogate endpoint. However, there are no known published reports about the value of PFS from the patient's perspective. We developed a questionnai...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2734-4

    authors： Hurvitz SA,Lalla D,Crosby RD,Mathias SD

    更新日期：2013-12-01 00:00:00

  • Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.

    abstract：:To investigate the prognostic value of tumor markers, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels at diagnosis of systemic recurrence. After primary treatments of locoregional breast cancers, serum CA 15-3 and/or CEA concentrations were regularly measured, and systemic recurrences were iden...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2695-7

    authors： Lee JS,Park S,Park JM,Cho JH,Kim SI,Park BW

    更新日期：2013-10-01 00:00:00

  • Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.

    abstract：:Endocrine therapy is an important therapeutic approach for the treatment of oestrogen receptor (ER)-positive breast cancer. However, a number of these endocrine therapies can fail when the tumour loses its ER expression during treatment. To date, few studies have explored the potential clinical significance of traditi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2263-6

    authors： Zhang B,Zhang X,Tang B,Zheng P,Zhang Y

    更新日期：2012-11-01 00:00:00

  • Femara and the future: tailoring treatment and combination therapies with Femara.

    abstract：:Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular pathways, resulting in the re-emergence of the disease. This is a distressing scenario for oncologists and patients, but recent intensive molecular and biochemical studies are beginning to unr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-007-9697-2

    authors： Ellis M,Ma C

    更新日期：2007-01-01 00:00:00

  • Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer.

    abstract：BACKGROUND:This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. PATIENTS AND METHODS:Thirty women, mean age 42.2 years (range 33-55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were elig...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01806158

    authors： de Vries EG,Rodenhuis S,Schouten HC,Hupperets PS,Dolsma WV,Lebesque JV,Blijham GH,Bontenbal M,Mulder NH

    更新日期：1996-01-01 00:00:00